Welcome to our dedicated page for Strata Critical Medical SEC filings (Ticker: SRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Strata Critical Medical, Inc. (Nasdaq: SRTA) provides access to the company’s regulatory disclosures as it executes its strategy in time-critical logistics and medical services for the U.S. healthcare industry. While no specific filings are listed here, Strata’s public communications reference documents such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which contain detailed financial statements, risk factors and management’s discussion of its organ logistics and medical services platform.
Through SEC filings, readers can review how Strata reports the performance of its air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion services, as well as perfusion staffing and equipment solutions offered under the Trinity Medical Solutions and Keystone Perfusion brands. The company also describes non-GAAP metrics like Adjusted EBITDA, Flight Profit, Flight Margin and various free cash flow measures, with reconciliations to GAAP figures typically presented in these filings or related materials.
Regulatory documents also summarize key corporate events that Strata highlights in its news releases, such as the divestiture of its Passenger business, the rebranding from Blade Air Mobility to Strata Critical Medical, the acquisition of Keystone Perfusion and the move to a single operating and reporting segment. Risk factor sections expand on themes the company mentions in press releases, including competition, reliance on transplant centers and organ procurement organizations, operational risks in organ transport and regulatory changes affecting its activities.
On Stock Titan, SEC filings for SRTA are supplemented with AI-powered summaries that explain complex sections in plain language, highlight important changes across reporting periods and help readers quickly identify disclosures related to organ logistics, medical services, acquisitions and non-GAAP performance measures. Real-time updates from EDGAR, combined with these summaries, make it easier to track how Strata’s regulatory reporting reflects its evolving business model in the U.S. healthcare and transplant ecosystem.
Strata Critical Medical delivered strong growth and turned profitable in the quarter ended March 31, 2026. Revenue rose to $67.4 million from $35.9 million, driven by 32.4% growth in Logistics to $47.6 million and new Clinical revenue of $19.8 million from the Keystone acquisition.
Gross profit doubled to $14.1 million, lifting total gross margin to 21.0% as higher‑margin Clinical work scaled. After $5.4 million of other non‑operating income, mainly fair value changes, Strata posted net income of $2.2 million versus a $3.5 million loss a year earlier, including a small loss from discontinued Passenger operations.
The company ended the quarter with $58.7 million in cash and cash equivalents, total assets of $327.6 million and stockholders’ equity of $285.7 million. A new $30 million asset‑based revolving credit facility was put in place and remained undrawn, providing additional liquidity for working capital and growth.
Strata Critical Medical reported strong first quarter 2026 results, with total revenue rising 87.4% year-over-year to $67.4 million, driven by 32.4% growth in Logistics revenue and the addition of its Clinical business. Gross profit doubled to $14.1 million, lifting gross margin to 21.0% from 19.6%.
The company generated net income from continuing operations of $2.4 million, compared with a loss of $1.6 million a year earlier, and delivered Adjusted EBITDA of $6.4 million, up sharply from $0.4 million. Operating cash flow reached $3.9 million, and Strata ended the quarter with $58.8 million in cash and short-term investments.
Clinical revenue rose 12.7% sequentially to $19.8 million, with Clinical gross profit up 29.2% versus Q4 2025. The company completed a bolt-on acquisition of Ohio Valley Perfusion Associates and reiterated its full-year 2026 guidance for revenue of $260–275 million, Adjusted EBITDA of $29–33 million, and free cash flow before aircraft and engine acquisitions of $15–22 million.
Strata Critical Medical reports that ARK Investment Management LLC and Catherine D. Wood beneficially own 7,455,284 shares of Common Stock, representing 8.57% of the class.
The filing allocates voting and dispositive authority: ARK holds sole voting and sole dispositive power over 7,455,284 shares while Catherine D. Wood holds shared voting and shared dispositive power over 7,455,284 shares. The Schedule 13G/A is signed and dated 04/30/2026.
Strata Critical Medical, Inc. CEO, Logistics Scott M. Wunsch reported equity compensation activity involving Class A common stock. On April 23, 2026, he acquired 57,172 shares at $0.0000 per share as a grant tied to performance-based restricted stock units that vested after meeting certified performance criteria.
On April 24, 2026, the company withheld 13,922 shares at $4.92 per share to cover tax obligations related to the PSU vesting, a non-market disposition. Following these transactions, he held 631,124 shares directly and 382,987 shares indirectly through a limited liability company he solely owns.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported compensation-related equity activity involving performance-based restricted stock units (PSUs). On April 23, he acquired 83,505 shares of Class A common stock at no cost upon certification that PSU performance criteria from a March 20, 2025 grant were met. On April 24, 40,960 shares were withheld by the company at $4.92 per share to cover tax withholding obligations tied to the PSU vesting. After these routine award and tax-withholding entries, Cohen directly holds 216,444 shares of Class A common stock.
Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported equity compensation activity in Class A common stock. On April 23, 2026, she acquired 630,264 shares at $0.00 per share from the vesting of performance-based restricted stock units. On April 24, 2026, 321,750 shares were disposed of at $4.92 per share, representing shares withheld by the company to cover tax obligations related to that vesting, not an open-market sale. After these transactions, she directly held 1,922,504 shares of Class A common stock.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported equity compensation activity involving the company’s Class A common stock. On April 23, 2026, he acquired 545,625 shares at $0.0000 per share upon vesting of performance-based restricted stock units granted on March 20, 2025, after the compensation committee certified that performance criteria were met.
On April 24, 2026, 301,731 shares were disposed of at $4.92 per share through shares withheld by the issuer to cover tax withholding obligations related to the PSU vesting, rather than an open-market sale. Following these transactions, Heyburn directly held 1,580,668 shares of Class A common stock.
Velibor Krstic filed an amended Schedule 13D showing a larger position in Strata Critical Medical’s public warrants and urging changes to their terms. He now beneficially owns 1,485,877 public warrants, or about 16.21% of the 9,166,644 public warrants outstanding as of April 15, 2026, plus 26,425 common shares.
Krstic invested approximately $25,291 of personal funds to build this warrant stake, including recent open‑market purchases at a weighted average price of about $0.017 per warrant. He advocates a mandatory exchange of warrants via amendment before their May 7, 2026 expiration, citing the company’s record 2025 Adjusted EBITDA of $14.1 million, a 2026 Adjusted EBITDA target of $29–$33 million, and over $110 million in total liquidity, including $61.2 million in cash and undrawn JPMorgan facilities.
Strata Critical Medical, Inc. calls a virtual 2026 annual stockholder meeting on May 28, 2026 at 9:00 a.m. Eastern to elect two Class II directors, ratify Deloitte & Touche LLP as auditor, and hold an advisory Say‑on‑Pay vote on 2025 executive compensation.
The company, formerly Blade Air Mobility, transformed in 2025 into a pure‑play medical logistics and services provider by selling its passenger business to Joby Aviation for approximately $76 million in Joby stock plus up to $45 million in holdbacks and earn‑outs, and acquiring Keystone Perfusion Services. It now operates Logistics and Clinical segments serving transplant and cardiovascular surgery customers.
Governance highlights include a classified Board, Co‑Chief Executive Officers William A. Heyburn and Melissa M. Tomkiel, and former CEO Robert Wiesenthal as Non‑Executive Chairman, with independent director Andrew Lauck expected to become Lead Independent Director after the meeting. The compensation program emphasizes pay for performance through cash bonuses tied mainly to Adjusted EBITDA and performance stock units.
Velibor Krstic filed an amended Schedule 13D reporting a significant warrant position in Strata Critical Medical, Inc. He beneficially owns 1,139,393 warrants, representing about 12.4% of the 9,166,644 public warrants outstanding as of the issuer’s latest annual report.
Krstic is a Swiss private investor who used approximately 19,380 dollars of personal funds to acquire these warrants, including 374,958 warrants bought on April 8, 2026 at a weighted average price of about 0.011 dollars per warrant. He also holds 26,425 shares of common stock, or roughly 0.03% of the 86,989,143 shares outstanding as of February 24, 2026.
He states that the warrants are significantly undervalued relative to the company’s fundamentals, citing Adjusted EBITDA of 14.1 million dollars and the integration of Keystone Perfusion. Krstic intends to monitor board and management decisions before the May 7, 2026 warrant expiration and may discuss potential actions such as a voluntary exchange offer or amendments to the warrant agreement, while noting no concrete plans under the specified regulatory categories.